Palantir Cofounder Joe Lonsdale Reportedly Backs Plan for 30,000-Monkey Farm in US to Ease AI Drug Discovery Bottleneck
AI-accelerated drug discovery has driven up demand and prices for lab monkeys. Palantir cofounder Joe Lonsdale is reportedly backing a 20-year US breeding plan, though biological cycles and welfare concerns pose challenges.
According to TechRadar, Palantir cofounder Joe Lonsdale is reportedly supporting Safer Human Medicine, a startup planning to establish a large-scale macaque breeding facility in the United States that would eventually house 30,000 monkeys. The initiative aims to address the supply pressure on animal test subjects caused by AI-accelerated drug discovery.
AI technology enables researchers to generate potential drug candidates more rapidly, increasing the need for toxicity, safety, and biological effect testing. Macaques are frequently selected due to their biological similarities to humans. However, US laboratories face severe shortages after China banned exports of lab monkeys in 2020 (previously accounting for about 60% of US imports) and alternative sources like Cambodia faced allegations of wild-caught animals being misrepresented as captive-bred. Reported prices for macaques have surged from approximately $3,000 in 2019 to over $20,000 today, a 700% increase.
Safer Human Medicine plans to gradually expand its population over approximately 20 years, starting with an initial stock of 500 to 1,000 macaques obtained from Asian facilities. However, female macaques typically reach reproductive maturity around four years of age and produce one offspring annually, meaning domestic capacity will take a long time to scale. Additionally, the plan has attracted criticism from animal welfare advocates, potentially leading to legal challenges that could further delay the project.